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ABSTRACT 
Parkinson’s disease (PD) is a multifactorial disorder with complex etiology. The most prevalent PD 
associated mutation, LRRK2-G2019S is linked to familial and sporadic cases. Based on the multitude 
of genetic predispositions in PD and the incomplete penetrance of LRRK2-G2019S, we hypothesize 
that modifiers in the patients’ genetic background act as susceptibility factors for developing PD. To 
assess LRRK2-G2019S modifiers, we used human induced pluripotent stem cell-derived 
neuroepithelial stem cells (NESCs). Isogenic controls distinguish between LRRK2-G2019S dependent 
and independent cellular phenotypes. LRRK2-G2019S patient and healthy mutagenized lines showed 
altered NESC self-renewal and viability, as well as impaired serine metabolism. In patient cells, 
phenotypes were only partly LRRK2-G2019S dependent, suggesting a significant contribution of the 
genetic background. In this context we identified the gene serine racemase (SRR) as a novel patient-
specific, developmental, genetic modifier contributing to the aberrant phenotypes. Its enzymatic 
product, D-serine, rescued altered cellular phenotypes. Susceptibility factors in the genetic 
background, such as SRR, could be new targets for early PD diagnosis and treatment. 
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factor, Serine racemase, second hit. 
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INTRODUCTION 
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease. 
Pathophysiologically, PD is characterized by the loss of midbrain dopaminergic neurons (DN) in the 
substantia nigra. The triggers that lead to the onset of PD and finally to DN degeneration are poorly 
understood and thus, PD pathogenesis remains largely elusive with no effective protective 
treatment.  PD has been proposed to encompass different multifactorial diseases, with similar 
phenotypic outcome (1). Multiple genetic predispositions, monogenetic mutations, and risk loci can 
cause similar parkinsonian phenotypes and symptoms.  
The most common mutation that causes autosomal dominant PD is a glycine to serine substitution 
at position 2019 (G2019S) in the leucine-rich-repeat-kinase-2 (LRRK2) (2,3). LRRK2 is of special 
interest as its mutations are the monogenetic cause of familial PD and the reason for 1-2 % of the 
sporadic cases (4,5). Furthermore, a single nucleotide polymorphism (SNP) in the LRRK2 gene acts as 
common risk modifier for developing PD (6). Epidemiologic studies suggest that the age of onset 
between individuals carrying LRRK2-G2019S is highly variable and that different ethnicities show 
higher prevalence’s (7). Accordingly genetic variations within the patient-specific genetic background 
may underlie this variability. Such so-called second hits may explain why asymptomatic carriers exist, 
why the penetrance of LRRK2-G2019S is age-dependent and why the LRRK2 phenotypic spectrum is 
practically indistinguishable from that of idiopathic PD (iPD) (4). 
Previous studies suggest that LRRK2 has an impact on neural stem cell (NSC) proliferation and 
integrity and plays a role in neurogenesis (8–12). Furthermore, LRRK2 expression is enhanced in the 
stem cell niches of the developing mouse brain during neurogenesis (13).  These observations imply 
a possible link between LRRK2, impaired neurogenesis, and the onset or progression of PD and 
therefore, we hypothezise that PD might have a neuro-developmental component that could explain 
DN vulnerability.  
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To explore this hypothesis, we investigated human PD patient-specific, iPSC-derived, neuroepithelial 
stem cells (NESC). To differentiate between LRRK2-G2019S dependent phenotypes and genetic 
background-specific changes, isogenic control lines were used (14). The identification of phenotypes 
in LRRK2-G2019S PD patient-specific NESCs allows to gain new insights into NSC deregulations in PD 
pathogenesis and development. Finally, analysing the patient genetic background enables to 
discover susceptibility factors that may control disease-related cellular phenotypes and predispose 
to PD. These novel genetic modifiers could potentially be used as biomarkers for early diagnosis or 
as personalized therapeutic targets for precision medicine.  
 
RESULTS 
Patient cell lines show impaired stem cell self-renewal and serine metabolism 
To get an unbiased overview of the pathways that are affected in patients compared to healthy 
individuals, we assessed the transcriptome of the healthy (H) vs. patients (P) NESCs lines depicted in 
Figure 1A. Quality controls regarding characterisation, derivation, gene-editing and individual 
absolute values of hNESCs phenotypes can be found in the supplements. Microarray analysis was 
performed and 865 significantly differentially expressed genes (DEGs) were identified between the 
six healthy and the six patient derived cell lines (H-6 vs. P-5), FDR ≤ 0.05 (15). Metacore pathway 
enrichment analysis revealed that the transcriptional regulation of amino acid metabolism, the cell 
cycle, cellular development as well as oxidative stress are within the top five networks enriched in 
the PD patients compared to healthy individuals (Figure 1B). We decided to focus the further 
analysis on the deregulated cell cycle and amino acid metabolism by assessing the corresponding 
phenotypes, such as metabolic activity, proliferation and cell death (Figure 1C-F). MTT assay derived 
growth curves revealed reduced cell viability or metabolic activity of the patient cell lines when 
compared to the healthy lines (H1-6 vs. P1-5) (Figure 1C). To link this decrease to lower proliferation 
rates and increased cell death, we stained for the mitosis marker phospho-histone H3 (PH3) (H1-6 
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vs. P1-5) and proliferation marker Ki67 (H1, H2, H6 vs P1, P2, P1.1). In the patient-derived lines, less 
cells were undergoing cell division as compared to healthy controls (Figure 1D and S3E). Moreover, 
immunostainings for cleaved caspase 3 (CC3) (H1-6 vs. P1-5) and for pyknotic nuclei (PYK) (H1-6 vs. 
P1-5), as well as flow cytometric counts for propidium iodide  (H1-2&4-5 vs. P1-5) revealed increased 
cell death and apoptosis in patient-derived lines (Figure 1E, 1F and S3E). 
Next, we used a metabolomics approach to investigate the intracellular levels of amino acids in the 
NESC cultures from healthy individuals and patients (H1-6 vs. P1-5) (Figure 1G). From all amino acids 
measured (H1-6 vs. P1-5), the L-serine increase in patients was the most promising candidate (Figure 
1H). Interestingly, the most decreased amino acid was phospho-serine, the precursor metabolite of 
serine (Figure 1G), suggesting that serine metabolism is deregulated in LRRK2-G2019S patients. This 
hypothesis is further strengthened by the investigation of serine levels in the blood plasma of 25 
healthy individuals, 25 iPD patients and 5 PD patients with the LRRK2-G2019S mutation (Figure 1I). 
(Figure 1I), suggesting that impaired serine metabolism is caused by LRRK2-G2019S. Furthermore, 
this observation supports the concept that findings from a PD patient-specific NSC model can be 
replicated in patients biofluids. 
 
Stratification of LRRK2-G2019S dependent and independent phenotypes 
Next, we investigated whether the phenotypes we observed in patient cells (Figure 1), were indeed 
caused by the LRRK2-G2019S mutation (Figure 2). For this purpose, we made use of the NESCs 
where the mutation had been introduced into the healthy background (H1, H3, H6.1 vs H1G2019S, 
H3G2019S, H6.1G2019S). We were able to detect phenotypes similar to the ones observed in patient 
lines, indicating that the LRRK2-G2019S mutation is sufficient to alter proliferation, cell death and 
metabolic activity (Figure 2A and B). Moreover, LRRK2-G2019S dependency of these phenotypes 
was highlighted by treatment with the LRRK2 inhibitor, CZC-25146, that was able to  rescue the 
mutation-depended increase in cell death and the decrease in mitosis (Figure S4A). We further 
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analyzed the serine levels upon the insertion of the mutation and could show that LRRK2-G2019S 
increases serine levels in hNESCs (Figure 2C). Furthermore, we also detected an increase in the 
serine levels in mice expressing human LRRK2-G2019S (Figure 2D). These observations, support the 
hypothesis that the observed serine deregulations are specific for the LRRK2-G2019S mutation. 
Next, we gene-corrected the LRRK2-G2019S mutation in the patient cell lines (P1, P1.1, P2 vs P1GC, 
P1.1GC, P2GC). Indeed, correcting the mutation resulted in the rescue of previously published  
phenotypes (16), such as increased protein levels of alpha-Synuclein and TAU (Figure S3A). 
Strikingly, the correction of the mutation was, not able to rescue proliferation and survival 
phenotypes in patient-specific NESCs (Figure 2E-G). Moreover, concerning the serine levels only a 
partial rescue can be observed (Figure 2H). This observation suggests that in the patient-derived 
lines, the genetic background is contributing to the phenotypes. To get further insights into the 
origin of the observed phenotypes and to delineate their dependency on LRRK2-G2019S, we 
repeated the proliferation and cell death assays in the presence of the LRRK2 kinase inhibitor CZC-
25146 (17). Previously, CZC-25146 was shown to rescue LRRK2-G2019S induced apoptosis in DNs 
(17). Within the PD patient-derived NESCs, increased cell death and decreased mitosis were not 
rescued by inhibiting LRRK2-kinase activity (Figure 2I and 2J). This observation suggests that other 
factors, which are independent of LRRK2-G2019S, strongly contribute to these  phenotype . 
Moreover, inhibiting LRRK2 in the gene-corrected cells had as expected no effect (Figure S4B). These 
results emphazise the finding that the gene-correction of LRRK2-G2019S was not sufficient to rescue 
the phenotypes and highlight the important contribution of the genetic background.  
 
Identification of potential susceptibility factors in the patient’s genetic background  
Based on the observation that cellular phenotypes partially depend on the information carried by 
the patient’s genetic background, we aimed at identifing responsible genes. For this purpose, we 
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reanalysed the gene expression via whole transcriptome microarray profiling taking into account 
also the isogenic controls. Moreover to narrow down, which genes could act as possible genetic 
modifiers, we performed a stricter analysis using the eBayes method (18). The data confirmed that 
deregulation of the NESC transcriptome is strongly influenced by the patient’s genetic background. 
The heatmap shows that patient cells cluster with their gene-corrected counterpart, suggesting a 
limited contribution of LRRK2-G2019S alone to the changes in gene expression (Figure 3A).  To 
investigate which genes could act as possible succeptibility factors accounting for the patients’ 
genetic background-dependent part of the phenotypes, we evaluated the DEGs from the Healthy vs. 
Patient comparison. The top 50 candidates are represented in a second heat map (Figure 3B). These 
top candidates include genes such as RAB32 and PTGR1 that have implications in LRRK2-G2019S 
induced PD pathogenesis (19) or were linked to the PD genetic background in DNs (20). To further 
emphasize the top candidate genes we performed a variable importance ranking based on the 
significance (Figure 3C) Interestingly, among the top five genes that were unique to the Healthy vs. 
Patient comparison we found 2 genes, ARL17a, ARL17b, in which SNPs have been linked to PD 
before (21) (Figure 3D). Other significant DEGs involved in pathways potentially relevant for PD, 
were serine racemase (SRR), neurotensin (NTS) and DLEU7 Antisense RNA 1 (DLEU7-AS1). The most 
promising candidates that may act as the here sought-after genetic modifiers were SRR and NTS 
because of their involvement in neuromodulation, -transmission and neurological diseases, such as 
PD (22,23).  
 
 
Patient cell lines show impaired SRR expression, deregulated serine metabolism and the 
enzymatic product of SRR, D-serine, rescues patient phenotypes. 
SRR is the enzyme that catalyzes the conversion between L-serine and D-serine (Figure 4A). Since 
serine metabolism was already affected by LRRK2-G2019S in hNESCs (Figure 1 and 2), we decided to 
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focus on SRR as a potential genetic modifier for LRRK2-G2019S induced PD. RT-qPCR for SRR mRNA 
validated the reduced expression in patient cell lines (H1-6 vs. P1-5) (Figure 4B). Consistent with the 
reduced SRR expression, the patient lines showed increased levels of L-serine compared to the 
healthy lines (H1-6 vs. P1-5) (Figure 4A). Therefore, we hypothesized that the reduced levels of SRR 
lead to increased levels of serine and a deficiency in the conversion to D-serine (Figure 4A).  Based 
on the described function of D-serine in NSCs (24,25), the deficiency in D-serine production might 
contribute to the observed cellular phenotypes, and consequently, the effects may be rescued 
through treatment with D-serine. Indeed, treatment with 100 µM D-serine led to the complete 
rescue of the proliferation and cell death phenotypes in PD patient-derived cells without affecting 
healthy lines (H1-6 vs P1-5) (Figure 4C). Strikingly, this rescue is specific for the NSC-related 
phenotypes. No rescue of the neuronal phenotypes (H1-6 vs. P1-5) was achievable through D-serine 
treatment (Figure S5).  Furthermore, D-serine was rescuing LRRK2-G2019S dependent phenotypes in 
the three healthy lines where we inserted the mutation (Figure S4C). In addition, D-serine rescued 
proliferation and partially rescued apotosis in the three patient lines where the mutation had been 
corrected (Figure S4D). These rescue effects highlight the contribution of impaired serine 
metabolism within the phenotypes and emphasizes the role of the LRRK2-G2019S mutation.  
 
DISCUSSION 
This study supports the concept that PD is not a monogenetic disease, a common interpretation of 
its diversity follows the multiple-hit hypothesis, which states that different incidences, or genetic 
predispositions may to act in parallel or consecutively to cause PD (26).  
Our data suggests that both a decrease in SRR expression caused by the genetic background as well 
as an increase of serine levels caused by LRRK2-G2019S influence serine metabolism. In patients 
both deregulations, the reduction of SRR caused by the genetic background and the LRRK2-G2019S 
mutation, may complement each other (Figure 4D).  Based on these results, we propose an interplay 
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between impaired serine metabolism, the PD genetic background and LRRK2-G2019S.  However, we 
are aware that some of the here presented results are unexpected and have clear constrains, 
including the facts that the sample sizes is limited and that some of the observed phenotypes are 
rather subtle or have marginal statistical significance. 
Initially, we thought that within patients LRRK2-G2019S alone leads to increased serine levels as 
observed in NESCs. Increased serine levels were, for instance, previously reported in the striatum of 
6-OHDa leasioned rats (27) and serine inversly correlates with PD progression, suggesting that it 
might inhere a compensatory mechanism (28). This view, however, was challenged in our data by 
the discrepancy that gene-correcting LRRK2-G2019S within the patient genetic background did not 
rescue phenotypes, meaning that other succeptibility factors contribute to phenotype 
manifestation. A screen for potential genes that could act as genetic modifier and represent the 
driving force behind the phenotypes identified SRR, which is directly involved in serine metabolism. 
We showed that cell lines having the patient background have decreased SRR expression, which is in 
accordance with existing transcriptomic data from the substania nigra of PD patients (29). 
Accordingly it seems more likely that two independent pathways exist that both affect serine 
metabolism and might act together under disease conditions.  Mouse studies showed for instance 
similar phenotypes in SRR-KO and LRRK2-G2019S mice, suggesting that LRRK2-G2019S and SRR 
might have opposing modulating capacities (8,30). The mechanism on how LRRK2-G2019S 
deregulates serine levels, however, remains an open question and the possibility of a direct 
interaction between both proteins cannot be excluded (Figure 4d).  
In regards to our hypothesis that PD may have a developmental component, patient NESCs show 
significant alterations in cell death and proliferation, which are both indicators of functionally 
relevant developmental impairments and could have significant consequences for in vivo 
neurogenesis. LRRK2 indeed is necessary for maintaining the balance between self-renewal and cell 
death in NESCs. Moroever, pathway analysis confirmed that developmental genes, independent of 
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LRRK2-G2019S, are altered between healthy and patient cell lines demonstrating that both LRRK2-
G2019S and the patient genetic background can influence organism development in the context of 
PD. 
Lastly, the deregulated serine metabolism by LRRK2-G2019S and decreased SRR expression levels 
consolidated the use of D-serine as potential rescue strategy. Moreover, a pilot study described that 
D-serine treatment alleviates behavioural and motor symptoms in PD (31). The fact that LRRK2 alone 
is not responsible for the investigated impairments, could have implications on PD therapeutic 
strategies in LRRK2-G2019S carriers. SRR, and L/D-serine could serve as new therapeutic targets for 
complementary treatment of early stage PD or may be used as potential blood biomarkers for 
diagnosis, stratification and preventive strategies. Finally, the results presented here might help to 
explain the incomplete penetrance and the variable age of onset and progression of LRRK2-G2019S 
carriers.  
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EXPERIMENTAL PROCEDURES 
Detailed experimental procedures are described in the supplements that can be found online. NESCs 
were generated from iPSCs, gene edited and cultivated as described by Qing et al., 2017 and 
Reinhardt et al., 2013. Antibodies and reagents for immunocytochemiststry can be found in Table 1. 
Confocal images were preprocessed with Zeiss and analysed using image J. MTT was performed 
using the manualfactures protocol (Sigma). Flow cytometry is described in Walter et al., 2019. RT-
qPCR was done using Taqman probes (Table 1). Metabolite blood and mouse extractions are 
described in Jäger et al., 2016 and cellular metabolites have been analysed by the University of 
Leiden. Mice were purchased from Jackson Lab Stock# 012467 derived from the WT funder line 
C5713467. Chemical reagents and treatments can be found in Table 1. RNA was extracted using 
miRNA easy kit. Samples were processed with EMBL Genomics Core Facility using Affymetrix Human 
Gene 2.0 arrays. GEO accession number GSE101534.  
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Figure 1. Patient cell lines show impaired stem cell renewal and serine metabolism compared to 
healthy hNESCs  
(A) Summary of cell lines: patients (P) healthy donors (H), insertion of LRRK2-G2019S (HG2019S) or 
gene correction (PGC).  
(B) Metacore pathway enrichement analysis for H1-6 vs. P1-5, based on 865 DEGs (RankProduct). 
(C) Growth curve of hNESCs by MTT at day 1, 3 and 6. Data as Mean ± SEM. *p≤0.05, 2-way ANOVA. 
Sidak’s multiple comparison *p<0.05 at day 6. N=6 (H1-6 vs. P1-5), n=5. 
 (D) Representative images of phenotypes. P hNESCs show decreased mitosis (pH3) and proliferation 
(Ki67). Quantifications as Mean ± SEM. *p≤0.05, t-test, GRUBB’s test α=0.1, no outlier, N=6 (H1-6 vs. 
P1-5), n=3. For Ki67 N=3 (H1-2, H6 vs. P1-2), n=3. See Figure S3F for individual values. 
(E) Propidium Iodide positive cell count after flow cytometry. Mean ± SEM. *p≤0.05, t-test, GRUBB’s 
test α=0.1, 1 outlier, N=5/6 (H1-2, H4-6 vs. P1-5) n=3. 
 (F) Representative images of phenotypes. P hNESCs show increased pyknosis (white stars) and 
apoptosis (CC3). Average percentages of positive cells ± SEM. *p≤0.05, t-test, GRUBB’s test α=0.1, no 
outlier for CC3, 1 outlier in H and P for PYK. N=6 (H1-6 vs. P1-5), n=3. See Figure S3F for individual 
values. 
(G) Intracellular amino acid metabolite levels of hNESCs show increased serine levels in P. Data is 
shown as logFC, Mean ± SEM.  
(H Serine metabolite levels in P vs. H individuals. Data is shown as Mean ± SEM p≤0.053, t-test. 
GRUBB’s  test within 3 technical and 3 biological replicates per line α=0.1. 1 outlier in H2, H3, H5 and 
P5. N=6 (H1-6 vs. P1-5), n=3. See also Figure S3B for individual values. 
(I) Serine blood plasma levels are increased in in P vs. H and in P vs. iPD cases. Mean ± SEM. *p≤0.05, 
t-test, GRUBB’s test α=0.1, no outliers. 1-way ANOVA p=0.0555. 
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Figure 2. LRRK2-G2019S is sufficient to increase cell death, and serine metabolism and to decrease 
proliferation and metabolic activity. However within patients, LRRK2-G2019S is not necessary to 
maintain phenotypes. 
(A) Representative images of HG2019S hNESCs. Introduction of LRRK2-G2019S in H cell lines 
increases pyknosis (Hoechst) and apoptosis (CC3) and reduces mitosis (PH3). Average percentage of 
positive cells ± SEM. *p≤0.05, **p≤0.01, ***p≤0.001, paired t-test, GRUBB’s test α=0.1, no outliers. 
N=3 (H1,H3,H6 vs. H1G2019S, H3G2019S, H6G2019S), n=3.   
(B) Growth curve of hNESCs by MTT after 1, 3 and 6 days. Mean ± SEM. 2-way ANOVA followed by 
Sidak’s multiple comparison *p<0.05 at day 6. N=2 (H1, H3 vs. H1G2019S, H3G2019S), n=5. 
 (C) Serine levels are increased in HG2019S vs. H individuals. Mean ± SEM. **p≤0.001, t-test, 
GRUBB’s test α=0.1, 1 outlier in H2, H3 and H5. N=2/6 (H1G2019S, H3G2019S vs. H1-6), n=3 
(D) Serine level in striatum of LRRK2-G201S carrying mice is increased compared to WT mice from 
the same strain. Mean ± SEM. *p≤0.05, t-test, GRUBB’s test α=0.1, 1 outlier in WT and G2019S. 
N=7/5. 
(E) Growth curve of hNESCs by MTT after 1, 3 and 6 days. Mean ± SEM. *p<0.05, 2-way ANOVA 
followed by Sidak’s multiple comparison. N=3 (P1-2 vs. P1-2GC), n=5. 
 (F) Representative images of PGC hNESCs. Gene correction is not rescuing reduced mitosis (PH3) 
and increased pyknosis (Hoechst) and apoptosis (CC3). 
(G) Quantification of B. Percentages as Mean ± SEM. *p≤0.05, paired t-test, GRUBB’s test α=0.1, 1 
outlier for PYK (P). N=3 (P1-2 vs. P1-2GC), n=3.  
(H) Serine levels are not significantly decreased by gene-correcting LRRK2-G2019S in patient lines. 
Mean± SEM, *p≤0.053, t-test, GRUBB’s test α=0.1, 1 outlier in P5 and P2GC. N=3 (P1-5 vs. P1-2GC), 
n=3. 
(I) Representative images of hNESCs stained for Hoechst, PH3 and CC3 after treatment with 0.5 µM 
LRRK2 Inhibitor CZC-25146 in DMSO.  
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(J) Quantification of D. Inhibition of LRRK2-G2019S is not rescuing reduced mitosis or cell death in 
patient lines. Data as Mean ± SEM. *p≤0.05, **p≤0.01, ***p≤0.001, t-test, GRUBB’s test α=0.1, 1 
outlier in Pdmso and PLRRK2in for CC3 and PYK and Hdmso for PH3, N=6 (H1-6 vs. P1-5), n=3.  
 
Figure 3. Identification of genes deregulated in LRRK2-G2019S carriers that might act as 
susceptibility factors within the patient genetic background to contribute to the observed 
phenotypes. 
(A) Heatmap showing clustering of the cell lines for the top 50 DEGs between H and P using the 
eBayes method, FDR≤0.05. 
(B) Heatmap of top 50 DEGs between H vs. P comparison, eBayes differential expression analysis, 
FDR≤0.05. N=6, n=3.  
(C) DEGs ranked by significance to identify the top candidates.  
(D) Top five DEGs between H and P are background dependent, *p<0.05 t-test, *FDR<0.05. Each dot 
represents one cell line. For H vs. P N=6 (H1-6 vs. P1-5), n=3. For PGC N=3 (P1-2GC), n=3. For 
HG2019S N=2 (H1G2019S, H3G2019S), n=3. 
 
Figure 4. SRR might contribute to deregulated serine metabolism, and D-serine the metabolic 
product of SRR rescues phenotypes in patients. 
(A) Validation of SRR expression by RT-qPCR. The H lines were set to 1. Mean ± SEM. *p≤0.05, t-test. 
N=6 (H1-6 vs. P1-5), n=3 
(B) SRR converts L-serine to D-serine and is downregulated in the patient genetic background.  
(C) Representative images of hNESCs stained with Hoechst, PH3 and CC3 after treatment with 100 
µM D-serine for 6 days. Quantification: D-serine rescues cell death and mitosis in patient cell lines; 
Mean ± SEM. *p<0.05, t-test, GRUBB’s test α=0.1, 1 outlier in Pser for PH3 and in Hser for CC3.  N=6 
(H1-6 vs. P1-5), n=3. 
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(D) SRR acts as genetic modifier for LRRK2-G2019S induced PD. Overview showing the synthesis of 
previous Figures. 
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Figure 2 Insertion of LRRK2-G2019S into healthy lines is sucient to cause phenotypes but within patients 
LRRK2-G2019S is not necessary  to maintain phenotypes
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Figure 4 D-serine rescues phenotypes as SRR might act as succeptibility factor within the patient background
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HIGHLIGHTS 
• Stem cells from LRRK2-G2019S patients show impaired self-renewal, viability, and serine 
metabolism. 
• Patient phenotypes only partly depend on LRRK2-G2019S, the PD genetic background 
contributes.  
• Identification of SRR as a possible susceptibility factor within the PD genetic background.  
• The enzymatic product of SRR, D-serine rescues background related phenotypes within PD 
patient cells. 
 
